DUBLIN, May 20, 2022--(BUSINESS WIRE)--The "Global RNA Based Therapeutic Market By Type, By Application, By End User, By Regional Outlook, Industry Analysis Report and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
The Global RNA Based Therapeutic Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 15.1 % CAGR during the forecast period.
RNA-based treatments have received a lot of popularity in recent years because of their potential to cure a wide range of chronic diseases like cancer, diabetes, AIDS, tuberculosis, and certain cardiovascular ailments, as well as uncommon and hereditary abnormalities. RNA-based treatments have been investigated as a viable treatment option for difficult-to-treat disorders, despite being in the clinical development phase.
The therapies are being developed using promising technologies such as RNA interference (RNAi), antisense technology, and smart technology. RNAi and antisense technology are gaining popularity in the research business because they give the base sequence for developing RNA therapeutics. The potential for RNA to be employed for therapeutic purposes has been explored, and specific problems have arisen during drug discovery and the implementation of RNA therapies.
Market Growth Factors:
An increasing number of chronic diseases and disorders
Demand is fueled by the presence of a large number of patients with infectious and chronic diseases. The desire for cures for infectious diseases and cancer is projected to influence the growth of the global RNA-based therapies and vaccine market. Moreover, according to the data shared by the WHO, Cancer is the second biggest cause of death worldwide, accounting for 9.6 million fatalities in 2018, or one in every six deaths. Men's cancers include lung, colorectal, stomach, prostate, and liver cancer, whereas women's cancers include breast, lung, cervical, colorectal, and thyroid cancer.In addition, the patient pool is large, which is expected to be another growth factor for the worldwide RNA-based therapies and vaccine market in the approaching years.
The rising popularity of personalized medicines
A large number of people are currently undergoing various drug courses as a result of a broad range of disorders. The remedies are made with a variety of salts and other ingredients and are intended for broad use. Regular drugs are supplied to clients in accordance with their treatment needs. Acids and salts, as well as other ingredients found in generic treatments, are not suitable for everyone. Due to RNA-based therapeutic, the practitioners are allowed to provide patients with personalized medicines based on their bodies' needs.
Marketing Restraining Factor:
Obstacles in the delivery of mRNA
Because mRNA is such a massive and hefty molecule (105 106 Da), successfully translating it into pharmaceuticals poses numerous problems. Additionally, mRNA is unstable and susceptible to nuclease degradation, as well as activating the immune system. In addition, because mRNA has a large negative charge density, it is less permeable across cell membranes. Because of these factors, mRNA is easily destroyed in the absence of a suitable delivery method, with a half-life of only around 7 hours. Despite the fact that chemical changes have helped to overcome some obstacles, mRNA delivery remains a challenge. Microinjection, RNA patches (mRNA loaded in a dissolving micro-needle), gene gun, protamine condensation, RNA adjuvants, and encapsulating mRNA in nanoparticles with lipids are some of the approaches that have been studied to increase mRNA delivery.
Market Segments Covered in the Report:
RNA Interference (RNAi)
Auto immune disorders
By End User
Hospitals & Clinics
Rest of North America
Rest of Europe
Rest of Asia Pacific
Rest of LAMEA
Key Market Players
Arbutus Biopharma Corporation
Arrowhead Pharmaceuticals, Inc.
Benitec Biopharma, Inc.
Alnylam Pharmaceuticals, Inc.
Sanofi S.A. (Sanofi Genzyme)
Ionis Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Silence Therapeutics Plc
For more information about this report visit https://www.researchandmarkets.com/r/dyce29
View source version on businesswire.com: https://www.businesswire.com/news/home/20220520005152/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900